Hosted on MSN10d
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts
Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%. Meanwhile, the ...
FDA Approves Non-Opioid Painkiller With No Addiction Risk
The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid ...
Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
American Association of Individual Investors3d
Which Is a Better Investment, Natera, Inc. or Vertex Pharmaceuticals Incorporated Stock?
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...